Access Pharmaceuticals signs eMarketing agreement with iMedicor

Access Pharmaceuticals, a biopharmaceutical company, has signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

Using iMedicor's highly targeted Alerts system application, initial introduction of MuGard to the 216,000 selected physicians in the US is expected to begin by the end of 2009.

MuGard is being commercially launched worldwide, with initial launches in the UK, Germany, Italy, Norway and Greece having been previously announced. Access expects additional commercial launches in Europe, and in the Far East through two partners to start shortly.

Jeffrey Davis, CEO of Access Pharmaceuticals, said: "We are excited about iMedicor's ability to introduce MuGard more rapidly and to a broad physician audience than we would expect through traditional distribution channels.

"We believe through this new marketing partnership with iMedicor, Access will be able to reach a broad spectrum of oncologists, radiation oncologists and other key clinicians in a very cost-effective manner, to utilize the medical education aspects of the system to educate about oral mucositis and MuGard, and to accelerate commercial uptake in the US market."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: ceo, commercial, education, europe, fda, germany, greece, italy, market, norway, partnership, pharmaceuticals, physicians